Safety and Effectiveness Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Hyperopia

Hyperopia Clinical Trial

Official title:

A Prospective, Randomized, Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of ≤ +6.0 D Of Hyperopia With Or Without Astigmatism Of +0.50 D To +3.50 D And MRSE ≤ +6.50 D

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00762281
• Other study ID #: MEL 80-2004-2
• Status: Completed
• Phase: N/A
• First received: September 26, 2008
• Last updated: August 9, 2012
• Start date: July 2004
• Est. completion date: October 2008

Study information

• Verified date: August 2012
• Source: Carl Zeiss Meditec, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the MEL 80 Excimer Laser is effective in the treatment of hyperopia, when used as part of the Laser In Situ Keratomileusis (LASIK) procedure.

Description:

LASIK has become one of the most common refractive eye procedures performed in the country. In the hyperopia procedure, a steepening occurs on the corneal surface, rather than the flattening procedure (myopic treatment). The surgeon will produce a standard keratomileusis flap using a microkeratome, exposing the corneal stroma. Recontouring under the flap is then accomplished by the removal of tissue from the stroma with the laser. This recontouring results in an altering of effective lens power of the central cornea, measured in diopters (D). The MEL 80 Excimer Laser System will be evaluated for its ability to create accurate and stable hyperopic refractive correction results.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 189
• Est. completion date: October 2008
• Est. primary completion date: October 2006
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Naturally occurring hyperopia up to +6.0 D, with or without astigmatism of +0.50 D to +3.50 D at the spectacle plane, and MRSE = +6.50 D;

• Have = 0.75 D of latent hyperopia as determined by the difference between the preoperative MRSE and CRSE;

• A stable refraction for at least the last 12 months as documented by previous clinical records, i.e., the spherical and cylindrical portions of the manifest refraction have not progressed at a rate of more than 0.50 D during the year prior to the baseline examination in the eye to be treated;

• Hard contact lens wearers must have two central keratometry readings and two manifest refractions taken at least one week apart that do not differ by more than 0.50 D;

• Visual acuity correctable to at least 20/40 in both eyes;

• Operative eye must be targeted for emmetropia;

• At least 21 years of age;

• Willing and able to return for scheduled follow up examinations for 24 months after surgery;

• Sign and be given a copy of the written Informed Consent form.

Exclusion Criteria:

• A history of anterior segment pathology, including cataracts (in the operative eye);

• Severe dry eye syndrome unresolved by treatment;

• Residual, recurrent, active ocular or uncontrolled eyelid disease, corneal scars within the ablation zone or other corneal abnormality such as recurrent corneal erosion or severe basement membrane disease;

• Ophthalmoscopic signs of keratoconus (or keratoconus suspect);

• An ablation deeper than 250 microns from the corneal endothelium;

• Irregular or unstable (distorted/not clear) corneal mires on central keratometry readings;

• Blind in the fellow eye;

• Undergone previous intraocular or corneal surgery of any kind in the operative eye(s), including any type of excimer laser surgery for either refractive or therapeutic purposes;

• A history of ocular Herpes zoster or Herpes simplex keratitis;

• A history of steroid-responsive rise in intraocular pressure, glaucoma, or preoperative IOP >21 mm Hg;

• Diabetes, diagnosed autoimmune disease, connective tissue disease, or clinically significant atopic syndrome;

• Immunocompromised or use chronic systemic corticosteroid or other immunosuppressive therapy;

• Pregnant, lactating, or be of childbearing potential and not practicing a medically approved method of birth control;

• A known sensitivity to planned study medications;

• Participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation;

• At risk for angle closure or for developing strabismus postoperatively.

• For Fellow (Second) Eyes in Simultaneous Bilateral Treatment Procedures

• 1. Flap complications during the first eye's surgery such as a free cap, partial flap, thin flap, or irregular flap.

• 2. Epithelial defect exceeding 2 mm x 2 mm in dimension, or clinically significant debris in the interface between the flap and underlying stroma for the first eye.

• 3. Severe blepharospasm in the first eye that may have prevented or impeded the completion of the keratectomy and/or the laser ablation procedure.

• 4. Poor subject cooperation with instructions for the first eye's surgery and/or poor subject fixation on the laser fixation target.

• 5. Aborted LASIK procedure in the first eye or PRK was performed in the first eye because LASIK was not possible.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hyperopia

Intervention

Device:
• MEL 80 Hyperopic LASIK Treatment
Treatment of Hyperopic corrections = +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE = +6.50 D.

Locations

Country	Name	City	State
United States	Texan Eye Care	Austin	Texas
United States	Fine, Hoffman, and Packer	Eugene	Oregon
United States	Dishler Laser Institute	Greenwood Village	Colorado
United States	Discover Vision Centers	Kansas City	Missouri
United States	Davis Duehr Dean Eye Clinic	Madison	Wisconsin
United States	US Navy Refractive Surgery Center	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
Carl Zeiss Meditec, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	At the point of stability, a minimum of 75% of eyes should have an achieved refraction within ± 1.00 D of the intended outcome, and at least 50% of eyes should be within ± 0.50 D of the intended outcome.		Point of stability	No
Primary	A minimum of 85% of eyes targeted for emmetropia should have an uncorrected visual acuity of 20/40 or better at the postoperative interval at which stability has been established.		Point of stability	No
Primary	A minimum of 95% of eyes should have a change of < 1.00 D in manifest refraction spherical equivalent (MRSE) between 2 refractions performed at least 3 months apart, and the mean rate of MRSE change per month should be < 0.04 D.		Point of stability	No
Primary	75% of eyes undergoing astigmatic treatment should be within ± 1.00 D of the attempted astigmatism correction by the point of stability.		Point of stability	No
Primary	Distance BSCVA of worse than 20/40 at the postoperative interval at which stability has been established should occur in less than 1.0% of eyes that had a BSCVA of 20/20 or better before surgery.		Point of stability	Yes
Primary	Loss of more than 2 lines of BSCVA should occur in less than 5.0% of eyes.		Point of stability	Yes
Primary	Less than 5% of eyes treated for sphere only should have a magnitude of postoperative manifest refractive astigmatism that varies from baseline cylinder by greater than 2.00 D at the postoperative interval at which stability has been established.		Point of stability	Yes
Primary	Incidence of Adverse Events to occur in less 1% of eyes		Postoperative visits	Yes
Secondary	Subject Satisfaction: As measured by a subjective questionnaire, and will be considered as a secondary efficacy variable.		Postoperative visits 3, 6, 9, 12, 18 and 24 months	No
Secondary	Incidence of Complications		Postoperative visits	Yes
Secondary	Patient Symptoms: As measured by a subjective questionnaire, will be considered as a secondary safety variable.		Preoperative and Postoperative visits 3, 6, 9, 12, 18 and 24 months	Yes